Vanguard Group Inc. Increases Stock Holdings in Oruka Therapeutics, Inc. $ORKA

Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 38.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,453,530 shares of the company’s stock after buying an additional 676,865 shares during the period. Vanguard Group Inc. owned approximately 0.05% of Oruka Therapeutics worth $74,366,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ORKA. Fairmount Funds Management LLC boosted its position in Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after purchasing an additional 333,340 shares during the last quarter. Secure Asset Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth $2,475,000. Avoro Capital Advisors LLC purchased a new position in Oruka Therapeutics in the third quarter worth $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Oruka Therapeutics in the third quarter worth $296,000. Finally, Commodore Capital LP boosted its position in Oruka Therapeutics by 23.5% in the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after purchasing an additional 333,340 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

ORKA has been the topic of several research analyst reports. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, April 30th. UBS Group boosted their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Thursday. Finally, Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $63.90 on Friday. The firm has a market cap of $3.21 billion, a PE ratio of -32.94 and a beta of -0.20. The stock’s fifty day moving average price is $54.63 and its two-hundred day moving average price is $39.18. Oruka Therapeutics, Inc. has a 1 year low of $8.91 and a 1 year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. Sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the sale, the insider owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 23,765 shares of company stock worth $1,089,745. Corporate insiders own 23.49% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.